



# Supplementary Figure S6.


A



B



C



**Supplemental Figure S6. Combination of olaparib + crizotinib decreases tumor growth in OVCAR8 and OC316 xenograft model. (A)** Tumor growth of OVCAR8 xenograft model.  $3 \times 10^6$  OVCAR8 cells were injected subcutaneously into female athymic nu/nu mice. Tumor bearing mice were randomized into 4 groups. Mice were treated with a single agent of olaparib and/or crizotinib for 6 weeks. The experiment was performed once. Tumor growth was evaluated weekly. Tumor growth were plotted with GraphPad. Two-way ANOVA test was performed for tumor growth. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  Error bars represent means  $\pm$  SD. **(B-C)** Tumor growth and tumor weight of ovarian cancer xenografts in female athymic nu/nu mice after treatment with olaparib, crizotinib alone or combination. OC316 cells ( $5 \times 10^6$ ) were injected intraperitoneally into nu/nu mice. Mice were randomized into 4 treatment groups (40 mg/kg olaparib ip, 15mg/kg crizotinib oral gavage or both) and treated for 4 weeks. After treatment, mice were sacrificed and **(B)** tumor weight was measured and **(C)** animal weight was measured. The tumor weight and animal weight of each individual mouse in each group is plotted ( $n=9$  in each group). Results were obtained using one-way ANOVA. \* $p < 0.05$ .